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Abstract 
 
Background: The commercially available synthetic angiotensin-I-converting enzyme (ACE) inhibitors are known to 
exert negative side effects which have driven many research groups globally to discover the novel ACE inhibitors. 
Method: Literature search was performed within the PubMed, ScienceDirect.com and Google Scholar. 
Results: The presence of proline at the C-terminal tripeptide of ACE inhibitor can competitively inhibit the ACE 
activity. The effects of other amino acids are less studied leading to difficulties in predicting potent peptide sequences. 
The broad specificity of the enzyme may be due to the dual active sites observed on the somatic ACE. The inhibitors 
may not necessarily competitively inhibit the enzyme which explains why some reported inhibitors do not have the 
common ACE inhibitor characteristics. Finally, the in vivo assay has to be carried out before the peptides as the 
antihypertensive agents can be claimed. The peptides must be absorbed into circulation without being degraded, which 
will affect their bioavailability and potency. Thus, peptides with strong in vitro IC50 values do not necessarily have the 
same effect in vivo and vice versa. 
Conclusion: The relationship between peptide amino acid sequence and inhibitory activity, in vivo studies of the active 
peptides and bioavailability must be studied before the peptides as antihypertensive agents can be claimed.  
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 Introduction 
 
According to Chen et al. (2012), in the year 2000, it was roughly estimated that about 972 million adults had 
hypertension. This number is expected to swell to a total number of 1560 million in 2025. Hypertension is associated 
with as a minimum of 7.6 million deaths annually worldwide (13.5% of all deaths), making it the primary risk factor 
for cardiovascular diseases (Chow et al., 2013). Currently, approximately 35% of the Latin American population, 20-
30% of the Chinese and Indian populations and approximately 14% of the Sub-Saharan African population suffer from 
hypertension (Mittal & Singh, 2010). In a national study of 16,440 subjects in Malaysia, the prevalence of hypertension 
in subjects aged 15 and above was 27.8%. The prevalence of hypertension among individuals aged 30 and above rose 
to 40.5% in 2004 compared to 32.9% in 1996. Among subjects aged 60 and above, the prevalence of hypertension was 
noted to be 69.3% in both sexes (Rampal et al., 2008).  
Different biochemical pathways are involved in regulating blood pressure such as the renin-angiotensin system 
(RAS), kallikrein-kinin system (KKS), and chymase that convert angiotensin I to angiotensin II (Li et al., 2004; 
Kanemitsu et al., 2006). Typically, RAS is widely associated with the regulation of the blood pressure since it plays a 
significant role in regulating arterial pressure. In this pathway, angiotensinogen is converted to angiotensin I by renin 
and later this angiotensin I is further cleaved to angiotensin II by angiotensin-converting-enzyme (ACE), which leads to 
the vasoconstriction of the artery and then to the elevation of blood pressure (Hong et al., 2008).  
ACE, a dipeptidyl carboxypeptidase (EC.3.4.15.1), plays an important role in the regulation of blood pressure. Apart 
from cleaving angiotensin I to induce vasoconstriction, it also inactivates bradykinin which functions as a vasodilator in 
KKS (Wijesekara & Kim, 2010; Jung et al., 2006).  
Two forms of ACE are present in humans; a somatic ACE of approximately 170 kDa found in endothelial, 
epithelial and neuronal cells and an approximately 100 kDa size of a smaller testicular isoform that exists in the 
germinal cells (Michaud et al., 2014). The somatic ACE is necessitated in cardiovascular regulation while germinal 
ACE is involved in male reproduction. According to Andujar-Sanchez et al. (2003), ACE is also present in the plasma 
in addition to the somatic and germinal forms. The plasma flowing ACE resulted by cleavage from the somatic form. 
The ACE inhibitors, calcium channel antagonists, beta and alpha blockers, natriuretic agents and endothelin receptor 
antagonists are groups of drugs which fall into the antihypertensive drug categories. For the treatments of high blood 
pressure and heart failure, the ACE inhibitors are the well-known drugs prescribed to patients. These drugs have also 
been shown to protect the organs from being damaged by diseases. For example, when administered alone or in 
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combination, Benazepril produces a renoprotective effect. Besides, when elevated blood pressure can be reduced within 
a normal range, Benazepril will prevent the cardiovascular disease (Saito, 2008; Barrios & Escobar, 2010). 
Despite the effectiveness, these drugs have undesirable effects like coughing, taste disturbance, kidney 
problem and angioneurotic oedema (Marczak et al., 2003). Hydrochlorothiazide and chlorthalidone can lessen 
potassium, magnesium, phosphorus, sodium, chloride, folate, B6, zinc, iodine, and CoQ10 while augmenting 
homocysteine, calcium, creatinine, glucose, insulin resistance, and type-2 diabetes mellitus at a rate of 5% annually 
(Alexander, 2014).  
Higher plasma homocysteine has been suggested as a risk factor for cardiovascular morbidity and mortality 
(Marcus et al., 2007), while the elevation in serum creatinine concentration within the normal range is an indicator for 
the augmented risk of cerebrovascular disease in both subjects of normotensive and hypertensive (Wannamethee et al., 
1997). The drugs also increase the occurrence of renal deficiency by more than 35% after 10 years of treatment. The 
administration of the first- and second-generation beta blockers to patients will lower CoQ10 while the ACE inhibitors 
and angiotensin-receptor blockers will lower zinc (Alexander, 2014). Besides that, the lichenoid reactions, white 
lesions categorized by linear striations on the buccal mucosa are sometimes noticed in the hypertensive patients 
resulting from the side effects of the ACE inhibitor drugs, particularly captopril (Kumar et al., 2012). Apart from the 
above mentioned problems, there is also a need to search for new antihypertensive drugs to overcome drug-resistant 
hypertension which occurs in approximately one in eight patients with elevated blood pressure (Townsend, 2011). 
Unlike these synthetic drugs, antihypertensive peptides do not show any adverse effect (Puchalska et al., 2015) 
although not all were tested for its toxicity. The inhibition of ACE is without a doubt the utmost studied mechanism to 
control the high blood pressure with respect to food derived biologically from active peptides. Most peptides have been 
noticed to inhibit ACE to a certain degree. The food industry has acknowledged the possibility of these natural 
antihypertensive agents as potential functional ingredients that can assist in the primary prevention and/or management 
of high blood pressure (Norris & FitzGerald, 2013). In this article, some of the ACE-inhibitory peptides derived from 
different protein sources, the ACE inhibition type, relationship between peptide amino acid sequence and inhibitory 
activity, in vivo studies of the active peptides, bioavailability and in silico bioavailability of the peptides are reviewed.  
 
The mechanism of action of angiotensin 
 
In order to induce constriction, angiotensin I has to be cleaved by the ACE to produce angiotensin II. This 
angiotensin II has the ability to bind to the angiotensin receptors AT1 and AT2, which are two principal angiotensin II 
receptor subtypes heterogeneously distributed in the peripheral tissues and brain (Chung et al., 1998). In the 
cardiovascular system, the AT1 receptor is ubiquitously expressed and facilitates most of the physiological and 
pathophysiological actions of Angiotensin II. The AT2 receptor is vastly expressed in developing foetus, and its 
expression is very little in the normal adult cardiovascular system. According to Lemarié and Schiffrin (2010), the 
angiotensin II physiological actions induced through the AT2 receptor opposes that of mediated by the AT1 receptor. 
While activation of the AT1 receptor by angiotensin II promotes the constriction of vascular beds, activation of the AT2 
receptors causes vasodilation. 
 
Relationship between the structure and activity of the ACE inhibitory peptide 
 
An understanding of the correlation between the peptide sequence and its bioactivity as an inhibitor is crucial 
in generating the potentially potent peptide ACE inhibitor. With the knowledge, it would reduce the need for long 
conventional ACE inhibitor peptide discovery approach. Unfortunately, there is inadequate information on the 
structure-activity relationship of antihypertensive peptides because current researches in bioactive peptide field are 
mainly focusing on the generation and characterization of the antihypertensive peptides.  
The first structural characteristic of the ACE-inhibitory peptides is the chain length. Out of many peptide 
sequences reported, potent ACE inhibitor peptides are typically short with 2-12 amino acids long (Norris & FitzGerald, 
2013). The short peptide sequences are easily absorbed into the blood circulation and retain their activity. This is most 
probably because oligopeptides may not be further digested into shorter fragments in the gastrointestinal tract and are 
readily absorbed into the circulation, and thus having good bioavailability. It is the best that the ACE inhibitory 
peptides should not have any enzymatic cleavage site for a gastrointestinal enzyme. However, depending on factors 
affecting the catalysis ability of these enzymes, it is possible that the peptides can escape from being degraded in the 
gastrointestinal tract. For example, proline and hydroxyproline comprising peptides are unaffected by the action of 
digestive proteases especially tripeptides with C-terminal Pro-Pro, which are resistant towards the proline-specific 
peptidases (Jao et al., 2012). 
Some oligopeptides (parent chain) may be cleaved into several smaller fragments. The outcome of the 
cleavage depends on the fragments produced where it may increase or reduce the overall ACE inhibition activity. The 
ACE inhibitory activity may increase if suitable amino acid such as proline is present at the C-terminal of the 
fragments. Thus, the degradation in the gastrointestinal tract may be beneficial in enhancing the activity of the inhibitor 
and similarly will cause the loss in the activity if the degradation causes the loss of a suitable structure needed to inhibit 
ACE activity. 
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Yet, several inhibitory peptides with longer sequences have been reported (Norris & FitzGerald, 2013). 
However, the biological efficacy of long peptide sequences cannot be determined through in vitro tests. In some cases, 
the good inhibitory activity observed in vitro is lost when in vivo assays are carried out and vice versa (Iwaniak et al., 
2014). Long peptides which are able to produce good ACE inhibitory effects most probably carry potent amino acids in 
the sequence, particularly within the four amino acids at the C-terminal of the sequence (Norris & FitzGerald, 2013). 
Depending on the nature of the peptide whether it is water or lipid soluble, these peptides may pass through the tight 
junction between cells of the paracellular or transcellular route, which explains the bioavailability of long peptides 
(Vermeirssen et al., 2004). 
Studies have shown that the C-terminal tripeptide sequence of an inhibitory peptide highly influences its 
binding by ACE. The published ACE inhibitory peptide sequences are listed in Table 1. Looking at the sequence, it 
seems there is a correlation between the IC50 values with a sequence of the peptides, where it could be predicted if a 
given sequence will be a good ACE inhibitor or not. Potent ACE inhibitors comprised of hydrophobic (aromatic or 
branched side chains) amino acid residues at the C-terminus where the utmost preferred is the presence of proline 
(Norris & FitzGerald, 2013). The presence of proline at C-terminal and antepenultimate position results in a good 
binding to the ACE, while the enzyme binds weakly if proline is present at the penultimate position of the peptide 
(Miguel et al., 2012). In many potent ACE inhibitor peptide sequences, tyrosine, phenylalanine, and tryptophan 
residues are also present at the C-terminus particularly for the di- and tripeptide inhibitors. The presence of 
hydrophobic amino acid leucine at the C-terminus also suggests that it may contribute to the ACE inhibition. In 
addition, the presence of positive charges on the side chains of arginine and lysine residues at the C-terminus have been 
identified to contribute to the peptide ACE inhibitory effectiveness (Norris & FitzGerald, 2013).  
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Table 1: Peptide sequences of ACE inhibitor from different sources and their IC50 value 
Source Preparation IC50 Peptide Reference 
Agaricus bisporus Ammonium sulphate precipitation 63  AHEPVK Lau et al., 2013 
Alaskan pollack Alcalase, pronase E, and collagenase 2.6 GPL Byun and Kim, 2001 
Alaskan pollack Pepsin 14.7  FGASTRGA Je et al., 2004 
Alaskan pollack Alcalase  pronase E 0.72  LGP Byun and Kim, 2002 
Algae Pepsin 29.6  VECYGPNRPQF Sheih et al., 2011 
Beef Thermolysin + proteinase A 23.2a VLAQYK Jang and Lee, 2005 
Blue mussel  Fermentation with 25% NaCl 19.34a EVMAGNLYPG Je et al., 2005 
Bonito  Thermolysin; boiling water extract 
5.1  
3.7  
IWHHT  
IY  
Yokoyama et al., 1992 
Bonito  Thermolysin; ACE 
2.4  
0.32  
LKPNM 
LKP 
Fujita and Yoshikawa, 
1999 
Bonito Autolysis 1.0  LRP Matsumura et al., 1993 
Bovine Alcalase  Pronase E 2.55  GPL Kim et al., 2001 
Bovine lactoferrin Pepsin  0.47 LIWKL  
Ruiz-Gimenez et al., 
2012 
Broccoli  Water extraction 10.5a YPK Lee et al., 2006a 
Buckwheat  Water extraction  6.25a GPP Ma et al., 2006 
Bullfrog  Alcalase 0.95  GAAELPCSADWW Qian et al., 2007b 
Canola meal Alcalase 0.15  VSV Wu et al., 2008b 
Catfish Thermolysin 0.86  GPPP Ghassem et al., 2012 
Chicken Aspergillus oryzae protease 29  GAXGLXGP Saiga et al., 2008 
Common fig Latex collection from tree 4.5 LYPVK Maruyama et al., 1989 
Corn  Pescalase 0.1b PSGQYY Suh et al., 1999 
Corn Alcalase 14.2  AY Yang et al., 2007 
Cotton leaf worm larvae 
Subsequent hydrolysis using pepsin, trypsin 
and chymotrypsin  
2123 AVF Vercruysse et al., 2008 
Cuttlefish Digestive proteases 6.1  VYAP Balti et al., 2010a 
Cuttlefish Bacterial proteases 11.6  AHSY  Balti et al., 2010b 
Dwarf gulper shark Thermoase 3.3a VW Ikeda et al., 2015 
Egg white Alcalase 20  RVPSL Liu et al., 2010 
Egg white lysozyme 
Combination of pepsin, α-chymotrypsin and 
trypsin 
2.86  VAW Rao et al., 2012 
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Garlic Aqueous extract 3.74  FY Suetsuna, 1998. 
Grass carp Alcalase 5.34a VAP Chen et al., 2012 
Grifola frondosa Water extract 2.6  KYTFAVTTVKTWV  Ohtsuru et al., 2000 
Hard clam Protamex 51  YN Tsai et al., 2008 
Hypsizygus marmoreus Water extract 190a LSMGSASLSP Kang et al., 2013 
Larva  Alcalase 17a YAN Dai et al., 2013 
Lizard fish Neutral protease 41  SPRCR Wu et al., 2012 
Lysozyme  Papain–trypsin 30a FESNFNTQATNR Asoodeh et al., 2012 
Microalgae Alcalase 128.4  VEGY Ko et al., 2012 
Milk 
Proteinase, aminopeptidas, x-prolyl-dipeptidyl 
aminopeptidase 
9.13 
5.15  
VPP 
IPP 
Pan et al., 2005 
Mung bean Alcalase 13.4  KLPAGTLF Li et al., 2006 
Ostrich egg white Trypsin 80.2  AFKDEDTEEVPFR 
Tanzadehpanah et al., 
2013 
Oyster Pepsin 66  VVYPWTQRF Wang et al., 2008a 
Pleurotus cornucopiae Water extraction 460a RLPSEFDLSAFLRA Jang et al., 2011 
Pleurotus cystidiosus Ammonium sulphate precipitation 62.8  AHEPVK  Lau et al., 2013 
Porcine  Thermolysin 549.0 ITTNP Arihara et al., 2001 
Porcine  Pepsin 6.1  KRVIQX Muguruma et al., 2009 
Porcine haemoglobin Pepsin 4.92 LGFPTTKTYFPHF Yu et al., 2006 
Porcine skeletal troponin Pepsin 26.2  KRQKYDI Katayama et al., 2008 
Porcine troponin C Pepsin 34  RMLGQTPTK Katayama et al. 2003 
Rainbow trout muscle Pepsin 63.9 KVNGPAMSPNAN Kim and Byun, 2012 
Rice Hydrolysate 4.5  VWP Chen et al., 2013 
Rice Alcalase 18.2 TQVY Li et al., 2007 
Rice wine  Concentrates 340a QFYAV Kang et al., 2012 
Salmon Alcalase  7.72 FNVPLYE Ahn et al., 2012 
Salmon skin Alcalase  papain 60a AP Gu et al., 2011 
Sardine Alkaline protease 1.63 KW  Matsufuji et al., 1994 
Sea bream Protease 7.5  VIY Fahmi et al., 2004 
Sea cucumber Bromelain and alcalase 15.9  MEGAQEAQGD Zhao et al., 2009 
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Sea cucumber Bromelain, alcalase 14.2a EDPGA Zhao et al., 2007 
Seaweed pipefish Alcalase 620a TFPHGP Wijesekara et al., 2011 
Sesame Thermolysin 0.78 LKY Nakano et al., 2006 
Shark Protease 1.45  FE Wu et al., 2008a 
Shrimp  
Fermentation by Lactobacillus fermentum SM 
605 
2.15  DP Wang et al., 2008b 
Silkworm albumin Acid protease (Asperqiius usamii NO. 537) 47a APPPKK Wang et al., 2011 
Sour milk 
Fermentation by Lactobacillus helveticus, 
Saccharomyces cerevisiae 
9  
5  
VPP 
 IPP 
Nakamura et al., 1995 
Soy bean Acid proteinase 
70 
65  
LAIPVNKP 
WL 
Kuba et al., 2005 
Soy bean Homogenization with dH2O 29.9  WL Kuba et al., 2003 
Soy bean Fermentation  2.2a HHL Shin et al., 2001 
Soy bean Rapid fermentation 43.7  LVQGS Rho et al., 2009 
Soybean  Protease P 1.69  VLIVP Gouda et al., 2006 
Spinach rubisco Pepsin-pancreatin  0.38  LRIPVA Yang et al., 2003 
Spirulina platensis Alcalase 5.77  IQP Lu et al., 2010 
Squid Esperase 47.78  GRGSVPAXGP Alemán et al., 2013 
Styela plicata Protamex 24.7 MLLCS Ko et al., 2011 
Sunflower Pepsin and pancreatin 6.9 FVNPQAGS Megias et al., 2004 
Tricholoma giganteum Water extraction 40a GEP Lee et al., 2004 
Tuna Pepsin  11.28 GDLGKTTTVSNWSPPKXKDTP Lee et al., 2010a 
Tuna Pepsin  21.6  WPEAAELMMEVDP Qian et al., 2007a 
Wakame  Pepsin 21  YNKL 
Suetsuna and Nakano, 
2000 
Wakame  Protease S “Amano” 1.5  IW Sato et al., 2002 
Walnut Hydrolysate  25.67a WPERPPQIP Liu et al., 2013 
Walnut Hydrolysate  128.98a LPGRPPIKPWPL Wang et al., 2014 
Yellowfin sole α-chymotrypsin 28.7a MIFPGAGGPEL Jung et al., 2006 
a= µg/mL; b= mM; while others are expressed in µM. 
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In the case of tetrapeptides, the best promising amino acids (beginning from C-terminus) are tyrosine and 
cysteine (Iwaniak et al., 2014). At the tetrapeptide second position, residues like histidine, tryptophan, and methionine 
are commonly found. In the peptide chain third position, residues such as isoleucine, leucine, valine, or methionine are 
positioned and tryptophan is located as the fourth residue (Iwaniak et al., 2014). However, this is not the only structure 
required for the inhibition. For example, the peptide GPPP with IC50 of 0.86 µM, apart from its shorter sequence which 
allows easy absorption, also shows significant inhibition due to the presence of proline at C-terminal and 
antepenultimate position. It can be concluded that the presence of proline can also play a significant role for the 
tetrapeptide inhibitor. The location of proline in this sequence best describes why it can significantly inhibit ACE.  
Two peptides (TKVIP and AYFYP) with proline residue present at the C-terminus studied by Maeno et al., 
(1996) did not produce strong ACE inhibitory activity. Although the proline residue is important in inhibiting ACE, 
this study has shown that the presence of proline alone at the C-terminal does not promise a good inhibition of the 
enzyme. In the same research, when KVLPVPQ was digested to a shorter KVLPVP, IC50 was improved from 1000 µM 
to 5 µM. This is possibly due to the presence of proline at C-terminal and also at the antepenultimate position of the 
peptide, which causes the peptide to bind stronger to the ACE active site as compared to the presence of proline at the 
penultimate position. The deletion of glutamine produced a better inhibition by placing proline at C-terminal and also 
the antepenultimate position of the peptide. 
When YKVPQL was partially hydrolysed by pancreatin to YKVP, IC50 of the peptide increased from 22 µM 
to more than 1000 µM (Maeno et al., 1996). The YKVP sequence was not a significant sequence for the ACE 
inhibition based on the amino acids arrangement. For a tetrapeptide sequence, tyrosine and cysteine are the best 
promising amino acids at the C-terminal and the sequence arrangement for tetrapeptide was explained by Iwaniak et al., 
(2014). As mentioned above, the GPPP sequence does not fit in this explanation and it is hypothesized that the presence 
of few prolines in tetrapeptides especially at the antepenultimate and C-terminal, will yield a good ACE inhibition.  
Generally, proline and hydroxyproline comprising peptides are unaffected by the digestive proteases (Jao et 
al., 2012).  
Compared to the original sequence of YKVPQL, the presence of proline at the antepenultimate position and 
leucine at the C-terminal are considered as a good sequence for increased potency. For a longer or oligopeptide 
sequence, the arrangement of the C-terminal amino acids is important so that the peptide can bind strongly to the ACE 
active site (Norris & FitzGerald, 2013).  
In another study of the long peptide, once the phenylalanine at the C-terminus of the GFXGTXGLXGF 
peptide was removed, IC50 was altered to 25000 µM from the original IC50 of 46 µM. This indicates that the presence 
of phenylalanine at C-terminus is also an utmost importance for the ACE inhibitory activity (Saiga et al., 2006). 
According to Ni et al., (2012), the peptides with phenylalanine at the C-terminal have high ACE inhibitory activity. 
Similar characteristic was observed for the peptide sequence of VECYGPNRPQF, with proline at the antepenultimate 
and phenylalanine at the C-terminal. 
Compared to the peptides described above, the ACE inhibitory activity of peptide LPGRPPIKPWPL was 
reported with lower IC50 value of 128.98 µg/mL. Although leucine is located at the C-terminal of the peptide, it does 
not necessarily make peptide a good inhibitor. Similarly, even though peptide has several proline residues, the position 
of this residue at the end of the C-terminal is really crucial. The presence of proline at the penultimate position will 
cause the peptide to bind weakly to the ACE active site (Miguel et al., 2012). 
The proline penultimate and antepenultimate positions are not really applicable for the tripeptide and 
dipeptide. Since the sequences are already short, the presence of proline may be exceptional. As mentioned above, the 
proline and hydroxyproline comprising peptides are unaffected to the action by the digestive proteases. Referring to 
Table 1, the results of tripeptides with proline at various positions such as VPP, IPP, GPP, GPL, LKP, and YPK give a 
good IC50 for ACE inhibition. Likewise, VSV produced a good IC50 of 0.15 µM. This probably suggests that the 
presence of valine at C-terminal for a tripeptide produces significant ACE activity reduction. To support this statement, 
Loponen, (2004) demonstrated that the VSP peptide sequence produced higher IC50 of 10 µM. Another characteristic of 
a good ACE inhibitor is the presence of glutamic acid at the C-terminal of the peptide. The good activity of such 
peptide can be explained by the ability of the peptide to chelate zinc by glutamic acid, which is a segment of the ACE 
active centre (Iwaniak et al., 2014). For example, the peptide FNVPLYE with a significant IC50 value consists of 
glutamic acid at the C-terminal.  
 
Kinetic study of the peptides 
 
In explaining the competitive inhibition of the inhibitors, the C-terminal tripeptide amino acids possibly will 
interact with the subsites S1, S1’, and S2’ at the active site of ACE. The zinc ion of ACE is correctly positioned 
between S1 and S1’ to contribute in the hydrolytic cleavage of the substrate peptide bond causing the release of the 
dipeptide product. ACE active sites S1, S1’and S2’ have high attractions for the side chains of tryptophan, alanine, and 
proline, respectively (Byun & Kim, 2002). Therefore, it can be concluded that ACE seems to favour substrates or 
competitive inhibitors that comprise hydrophobic amino acid residues at the three locations of the C-terminal which 
will interact with these subsites (Hong et al., 2008). Thus, Tovar-Pérez et al. (2009) recommended that active naturally-
occurring ACE inhibitory peptides should comprise proline or aromatic amino acids. They also suggested that the 
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broad substrates or inhibitor specificity of the enzyme may be due to the two active enzymatic sites in ACE. The 
somatic ACE comprises two homologous domains, both bearing a functional active site.  
To prove the in vivo involvement of each active site in releasing angiotensin II and the inactivation of bradykinin, 
radiolabeled angiotensin I and bradykinin act as the ACE physiological substrates were deployed in in vitro and in vivo 
studies to expand understandings into the functional roles of these dual active sites of somatic ACE. In vitro 
experiments showed that a complete inhibition of the angiotensin I and bradykinin cleavage needs a blockade of the 
dual ACE active sites. Oppositely, the in vivo studies in mice revealed that the selective inhibition of either the N-
domain or the C-domain of ACE by these inhibitors reduced the conversion of angiotensin I to angiotensin II; however, 
bradykinin protection involves the inhibition of the dual ACE active sites (Georgiadis et al., 2003). 
According to Chen et al. (2010), the somatic angiotensin-I-converting enzyme (sACE) isolated from the pig 
lung had a molecular weight of 180 kDa. Upon the proteolytic cleavage, two fragments with the size of about 90 kDa 
were attained and identified by amino-terminal sequence analysis and later known as N- and C-domains of sACE 
where each domain comprises a functional Zn2+ binding active centre (Danilov et al., 2014). The germinal ACE which 
is smaller than sACE composes only a single catalytically active domain alike to the C-domain. To some extent, N- and 
C-domains of sACE have a different enzymatic activity where the C-domain is better in converting Ang I into Ang II 
but having similar efficiency in cleaving bradykinin (Michaud et al., 2014).  
Some peptides do not have clear amino acid sequences for example GDLGKTTTVSNWSPPKXKDTP from 
the tuna frame and yet had a significant ACE inhibitory activity with IC50 of 11.28 µM and noncompetitively inhibited 
ACE (Lee et al., 2010a). It is possible that these peptides are non-competitive inhibitors where they did not bind to the 
active site of ACE. Several research groups have determined the type of inhibition of their peptides. To our knowledge, 
the reported ACE inhibitors are either competitive or non-competitive inhibitor based on the Lineweaver-Burk graph 
plotted (Table 2). 
Interestingly, Ni et al., (2012) have shown that the yeast-derived hexapeptide, TPTQQS, non-competitively 
inhibited ACE by binding N-terminal helices of ACE while its serine residue attracts the zinc residue in the active site, 
resulting in the conformational change of the active site. Thus, even though substrates can bind to the active site 
catalysis cannot be carried out.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Manoharan et al., Afr J Tradit Complement Altern Med., (2017) 14 (2): 383-406 
doi:10.21010/ajtcam.v14i2.39 
391 
 
Table 2: ACE inhibitory peptides and its inhibition mode 
 
Source  Peptide  Type of inhibitor References  
Alaska pollack FGASTRGA  Non-competitive  Je et al., 2004 
Algae  VECYGPNRPQF Non-competitive Sheih et al., 2009 
Bigeye tuna dark muscle WPEAAELMMEVDP  Non-competitive  Qian et al., 2007a 
Bovine lactoferrin LRPVAA Non-competitive  Lee et al., 2006b 
Bullfrog muscle protein GAAELPCSADWW Non-competitive Qian et al., 2007b 
Cuttlefish  AHSY Non-competitive  Balti et al., 2010b 
Dwarf gulper shark VW Competitive  Ikeda et al., 2015 
Freshwater zooplankton AQGERHR Competitive Lee et al., 2010b 
Hen egg white lysozyme MKR, RGY, VAW Competitive Rao et al., 2012 
Manchego cheese  VRYL Competitive Ruiz et al., 2004 
Marine Chlorella ellipsoidea VEGY Competitive  Ko et al., 2012 
Mushroom GEP Competitive Lee et al., 2004 
Mushroom  AHEPVK Competitive Lau et al., 2013 
Mushroom  
RIGLF 
PSSNK 
Competitive 
Non-competitive 
Lau et al., 2014 
Oyster VVYPWTQRF Non-competitive Wang et al., 2008a 
Porcine VVYPWT LGFPTTKTYFPHF Competitive  Yu et al., 2006 
Rainbow trout muscle KVNGPAMSPNAN  Competitive  Kim and Byun., 2012 
Rice VNP, VWP Competitive Chen et al., 2013 
Salmon VWDPPKFD Non-competitive Ahn et al., 2012 
Soybean VLIVP Competitive Gouda et al., 2006 
Spirulina platensis IQP Non-competitive  Lu et al., 2010 
Tofuyo IFL, WL Non-competitive Kuba et al., 2003 
Tuna frame GDLGKTTTVSNWSPPKXKDTP Non-competitive  Lee et al., 2010a 
Turtle egg white IVRDPNGMGAW Competitive Rawendra et al., 2013 
Wakame 
VY, VW 
IY, LW 
AW, FY, IW 
Competitive 
Non-competitive 
Un-competitive 
Sato et al., 2002 
Yeast TPTQQS Non-competitive Ni et al., 2012 
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In vivo studies and bioavailability of ACE inhibitory peptides 
 
The ACE inhibitory percentages observed in vitro by a peptide do not always correlate with the in vivo effect 
when administered in spontaneously hypertensive rats (SHR). There are many factors contributing to the effectiveness 
of the peptides once they are administrated in vivo. The digestion by gastrointestinal enzymes would be the first factor 
causing the loss of the peptide availability where the degraded peptides may no longer have a structure suitable to 
inhibit ACE. Secondly, as mentioned previously, the size of peptides may affect the absorption and thus, their 
availability. On top of that, in vitro analysis typically only focuses on one inhibition of ACE and yet there are many 
pathways involved in regulating blood pressure. Once administered into the body, there is a possibility that the peptide 
may also interact with enzymes other than ACE or that the inhibition of ACE alone would not be sufficient to reduce 
blood pressure. These activities will lead to the incomparable outcome between the in vivo and in vitro study. The 
blood pressure lowering effects by the ACE inhibitory peptide on SHR are listed in Table 3.   
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Table 3: Blood pressure lowering effect by ACE inhibitory peptide in SHR 
Source  Peptide  Dose mmHg reduction Reference  
Bigeye tuna dark muscle WPEAAELMMEVDP 10 mg/kg ~17 mmHg Qian et al., 2007a 
Blue mussel EVMAGNLYPG 10 mg/kg 19 mmHg Je et al., 2005 
Bullfrog GAAELPCSADWW 10 mg/kg 10 mmHg Qian et al., 2007b 
Chlorella ellipsoidea VEGY 10 g/kg 22.8 mmHg Ko et al., 2012 
Corn gluten meal AY 50 mg/kg 9.5 mmHg Yang et al., 2007 
Dried bonito LKPNM 100 µg/kg 30 mmHg Fujita and Yoshikawa, 1999 
Dried bonito IKP 10 mg/kg 70 mmHg (IV route) Fujita et al., 2000 
Egg white RVPSL 50 mg/kg 
24 mmHg (compared to  
negative control) 
Yu et al., 2014 
Garlic 
SY  
GY  
FY  
NY 
SF 
GF 
NF 
200 mg/kg 
~50 mmHg 
~52 mmHg 
~32 mmHg 
~35 mmHg 
~39 mmHg 
~25 mmHg 
~54 mmHg 
Suetsuna, 1998 
Oyster VVYPWTQRF 20 mg/kg ~32 mmHg Wang et al., 2008a 
Porcine myosin B KRVIQX 10 mg/kg 23 mmHg Muguruma et al., 2009 
Porcine skeletal muscle 
troponin  
KRQKYDI 10 mg/kg 9.9 mmHg Katayama et al., 2008 
Rice 
VNP 
VWP 
5 mg/kg 
29 mmHg 
38 mmHg 
Chen et al., 2013 
Rice  TQVY 30 mg/kg ~40 mmHg Li et al., 2007 
Sea cucumber MEGAQEAQGD 3 μM/kg ~17 mmHg Zhao et al., 2009 
Skimmed milk 
VPP 
1.80 mg/kg 
3.60 mg/kg 
~17 mmHg 
~25 mmHg 
Pan et al., 2005 
IPP 
1.20 mg/kg 
1.80 mg/kg 
~25 mmHg 
~29 mmHg 
Soybean HHL 5 mg/kg 
32 mmHg (single injection) 
61 mmHg (triple injection) 
Shin et al., 2001 
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Spinach rubisco 
MRW 
MRWRD 
IAYKPAG 
LRIPVA 
20 mg/kg 
30 mg/kg 
100 mg/kg 
100 mg/kg 
20 mmHg 
13.5 mmHg 
15 mmHg 
0 mmHg 
Yang et al., 2003 
Tenebrio molitor (L.) larvae YAN 400 mg/kg 27 mm Hg Dai et al., 2013 
Tuna frame GDLGKTTTVSNWSPPKXKDTP 10 mg/kg 21 mmHg Lee et al., 2010a 
Wakame 
AIYK 
YKYY 
KFYG 
YNKL 
50 mg/kg 
~38 mmHg 
~48 mmHg 
~42 mmHg 
~52 mmHg 
Suetsuna and Nakano, 2000 
Yellowfin sole MIFPGAGGPEL 10 mg/kg 22 mmHg Jung et al., 2006 
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Digestion of ACE inhibitory peptides 
 
In the digestive tract, proteinases and peptidases may degrade or reduce the activity of peptide and thus, it is 
utmost importance that the peptide needs to be resistant to the enzymes if an intact peptide is required to inhibit ACE. 
In the stomach, the acidic pH favours pepsin to digest proteins and peptides. Later, the action of pancreatic proteases, 
trypsin, α-chymotrypsin, elastase, and carboxypeptidases A and B further shorten polypeptides at more alkaline pH. In 
the in vitro model, the bioavailability of bioactive peptides is commonly confirmed by successive hydrolysis with 
pepsin and pancreatic enzymes so as to mimic the gastrointestinal condition.  
It has been reported that during the simulated gastrointestinal digestion, the peptide inhibitory activity reduces 
(Norris & FitzGerald, 2013; Jao et al., 2012). After the simulated digestion on a potent ACE inhibitory peptide 
YLVPQL, a peptide YLVP with low ACE inhibitory activity was produced which resulted in a non-significant 
antihypertensive effect in SHR (Jao et al., 2012). Casein-derived ACE inhibitory peptide KVLPVPQ was cleaved to 
KVLPVP in the simulated gastrointestinal digestion and produced similar ACE inhibitory activity (Maeno et al., 1996). 
When these peptides were administered orally to SHR at the dose of 2 mg/kg, a reduction in the systolic blood pressure 
was recorded at 32.2 and 31.5 mmHg, respectively. Thus, a similar pattern could be observed between the in vitro and 
in vivo analysis.  
Therefore, a prediction on how stable a peptide is against gastrointestinal digestion may be helpful in deducing 
the availability of peptide sequence after oral administration. In Table 4, with the aid of BIOPEP database, the stability 
of peptides listed in Table 1 was tested against the gastrointestinal enzymes trypsin, chymotrypsin, and pepsin. The 
BIOPEP application comprises a database of biologically active peptide sequences and a program facilitating the 
creation of profiles of the potential biological activity of protein fragments, calculation of quantitative descriptors as 
measures of the value of proteins as the potential precursors of bioactive peptides, and the prediction of bonds 
susceptible to the hydrolysis by endopeptidases in a protein chain (Minkiewicz et al., 2008). Out of 75 ACE inhibitory 
peptide sequences, only 12 were predicted to be stable against the action of these three enzymes. There are many more 
enzymes present in the gastrointestinal tract and the fate of these 12 peptides are not known although several peptides 
like IPP and VPP can be absorbed into circulation without being cleaved (Ryan et al., 2011). From Table 4, the reason 
why several peptides lost their activity in vivo although yielded significant result in vitro or vice versa could be 
hypothesized. For example, the peptide TQVY from rice produced an IC50 value of 18.2 µM but based on the 
prediction, pepsin can cleave this sequence and release TQ-VY. From the BIOPEP database, it was suggested that TQ 
and VY are two dipeptides with ACE inhibitory characteristic. As predicted, when TQVY was administered to SHR, a 
significant reduction in blood pressure of 40 mmHg was observed (Li et al., 2007). It is possible the reduction of blood 
pressure was due to these two dipeptides, rather than the intact peptide. In another study, a peptide AVF yielded the 
IC50 value of 2123 μM and from the IC50 value (Vercruysse et al., 2008), it was predicted that this peptide will not give 
a significant reduction of elevated blood pressure in vivo. Interestingly, AVF was predicted to be cleaved to A-VF by 
pepsin. The peptide VF was suggested as the ACE inhibitor by the database. Although the inhibitory activity of the 
intact peptide was weak in vitro, it is possible that peptide could have a better activity in vivo due to the digestion. 
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Table 4: Hydrolysis of ACE inhibitor peptides by trypsin, pepsin and chymotrypsin as predicted by BIOPEP database 
Original sequence Trypsin  Pepsin (pH > 2) Chymotrypsin (A) 
  Low IC50  
AHEPVK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             AHEPVK A - HE - PVK AHEPVK
AHSY AHSY A - HSY AHSY 
AP AP A-P AP 
AY AY A-Y AY 
DP DP DP DP 
EDPGA EDPGA E - DPGA EDPGA 
EVMAGNLYPG EVMAGNLYPG E - VMA - GNL - Y - PG EVMAGNL - Y - PG 
EVSQGRP EVSQGR - P E - VSQ - GRP EVSQGRP 
FNVPLYE FNVPLYE F - NVPL - Y - E F - NVPL - Y - E 
FVNPQAGS FVNPQAGS F - VNPQ - A - GS F - VNPQAGS 
FY FY F-Y F-Y 
GEP GEP GE - P GEP 
GPL GPL GPL GPL 
GPP GPP GPP GPP 
GPPP GPPP GPPP GPPP 
HHL HHL HHL HHL 
IPP IPP IPP IPP 
IW IW IW IW 
IVY IVY IVY IVY 
KRQKYDI K - R - QK - YDI KRQ - KY - DI KRQKY - DI 
KVNGPAMSPNAN K - VNGPAMSPNAN KVNGPA - MSPNA - N KVNGPAMSPNAN 
LAIPVNKP LAIPVNK - P L - A - IPVNKP L - AIPVNKP 
LGFPTTKTYFPHF LGFPTTK - TYFPHF L - GF - PTTKTY - F - PHF L - GF - PTTKTY - F - PHF 
LIWKL LIWK - L L - IW - KL L - IW - KL 
LKPNM LK - PNM L - KPNM L - KPNM 
LKY LK - Y L - KY L - KY 
LRIPVA LR - IPVA L - RIPVA L - RIPVA 
LVQGS LVQGS L - VQ - GS L - VQGS 
LW LW L - W L - W 
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LY LY L - Y L - Y 
LYPPP LYPPP L - Y - PPP L - Y - PPP 
MEGAQEAQGD MEGAQEAQGD ME - GA - Q - E - A - Q - GD MEGAQEAQGD 
MIFPGAGGPEL MIFPGAGGPEL MIF - PGA - GGPE - L  MIF - PGAGGPEL 
MLLCS MLLCS ML - L - CS ML - L - CS 
MVGSAPGVL MVGSAPGVL MVGSA - PGVL MVGSAPGVL 
RVPSL R - VPSL RVPSL R VPSL 
SPRCR SPR - CR SPRCR SPRCR 
TQVY TQVY TQ - VY TQVY 
VAP VAP VA-P VAP 
VAW VAW VA - W VAW 
VECYGPNRPQF VECYGPNR - PQF VE - CY - GPNRPQ - F VECY - GPNRPQF 
VELYP VELYP VE - L - Y - P VEL - Y - P 
VLIVP VLIVP VL - IVP VL - IVP 
VPP VPP VPP VPP 
VSV VSV VSV VSV 
VVYPWTQRF VVYPWTQR - F VVY - PW - TQ - RF VVY - PW - TQRF 
VW VW VW VW 
VWP VWP VW - P VW - P 
VYAP VYAP VY - A - P VY - AP 
WL WL W-L W-L 
WPERPPQIP WPER - PPQIP W - PE - RPPQ - IP W - PERPPQIP 
YAN YAN Y - A - N  Y-AN 
YI YI Y - I Y - I 
YN YN Y-N Y-N 
YNKL YNK - L Y - NKL Y - NKL 
YPK YPK Y-PK Y - PK 
LKP LK-P L-KP L-KP 
FE FE F-E F-E 
GAAELPCSADWW GAAELPCSADWW GA - A - E - L - PCSA - DW - W GAAEL - PCSADW - W 
APPPKK APPPK - K A - PPPKK  APPPKK 
IQP IQP IQ-P IQP 
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FESNFNTQATNR FESNFNTQATNR F - E - SNF - NTQ - A - TNR F - ESNF - NTQATNR 
  Moderate IC50  
AFKDEDTEEVPFR AFK - DEDTEEVPFR A - F - KDE - DTE - E - VPF - R AF - KDEDTEEVPF - R 
AWLHPGAPKVF AWLHPGAPK - VF A - W - L - HPGA - PKVF AW - L - HPGAPKVF 
GMNNLTP GMNNLTP  GMNNL - TP GMNNL - TP 
HLFGPPGKKDPV HLFGPPGK - K - DPV HL - F - GPPGKKDPV  HL - F - GPPGKKDPV 
LPGRPPIKPWPL LPGR - PPIK - PWPL L - PGRPPIKPW - PL L - PGRPPIKPW - PL 
LSMGSASLSP LSMGSASLSP L - SMGSA - SL - SP L - SMGSASL - SP 
VEGY VEGY VE - GY VEGY 
  High IC50  
AVF AVF A-VF AVF 
ITTNP ITTNP ITTNP ITTNP 
QFYAV QFYAV Q - F - Y - A - V QF - Y - AV 
RLPSEFDLSAFLRA R - LPSEFDLSAFLR - A RL - PSE - F - DL - SA - F - L - RA RL - PSEF - DL - SAF - L - RA 
TFPHGP TFPHGP TF - PHGP TF - PHGP 
YAHYSYA  YAHYSYA Y - A - HY - SY - A  Y - AHY - SY - A 
Peptide sequences in green colour are the peptides which can exert ACE inhibitory activity as predicted by BIOPEP database.  
Peptide sequences in red colour are the peptides which can exert ACE inhibitory activity based on its characteristics as predicted by the authors. Some of the sequences in red have 
been reported earlier.  
BIOPEP database does not obey the Keil rule. Generally, Keil rule is defined as trypsin cleaves next to amino acid arginine (R) or lysine (K), but not before proline (P) (Rodriguez et 
al., 2008). 
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Due to the complexity of the blood pressure regulation system the in silico digestion should not be taken as a 
definitive outcome; there were in vivo data which cannot simply be explained by the problem of digestion. For 
example, YGGY did not produce any reduction in the elevated blood pressure when administered orally to SHR even at 
the dose of 100 mg/kg despite its IC50 value of 3.4 µM (Saito et al., 1994). Its digested product also has a good 
inhibitory activity. YGGY can be cleaved by pepsin pH >2 to Y-GGY. The tripeptide, GGY was suggested as an ACE 
inhibitor by BIOPEP database where this tripeptide was reported to have the IC50 value of 1.3 µM (Shamloo et al., 
2015). To a lesser extent, the released amino acid tyrosine can also exert ACE inhibitory activity on its own as shown 
by Sved et al. (1979). When tyrosine was given intraperitoneally at the dose of 50 mg/kg and 200 mg/kg, about 12 mm 
Hg and 40 mm Hg reductions were observed, respectively. Thus, other factors may explain the loss of its ACE 
inhibitory activity (Section 5.4).  
Another interesting example is the peptides YPI and RADHP with the IC50 value of more than 1000 µg/mL 
and 153 µg/mL respectively before and after the digestion. These peptides were derived from YAEERYPIL and 
RADHPFL respectively, where the parent peptides possess the in vitro ACE inhibitory effect. However, these peptides 
(YPI and RADHP) can significantly reduce the elevated blood pressure in SHR at the dose of 2 mg/kg, even though 
both peptides are considered as weak inhibitors based on the in vitro studies. The authors concluded that the peptides 
possibly did not exert the antihypertensive effect via ACE inhibitory mechanism (Miguel et al., 2006). 
 
Absorption of ACE inhibitory peptides 
 
When given orally, peptides should be absorbed in the intestine and induce the effect once they reach the 
target site. Several proteins or peptide structures are noted to be resistant to the action of gastrointestinal digestion, 
depending whether they have sequences recognized by the digestive enzymes. Peptides with proline and hydroxy 
proline residues have been noted being resistant towards hydrolysis. Similarly, modified peptides such as glycopeptides 
and Maillard reaction products were shown to be resistant towards the GI tract enzyme cleavage (Norris & FitzGerald, 
2013).  
Peptides must also be transported through the brush border membrane intact and be resistant towards the 
serum peptidases. By mean of a specific peptide transport system for example peptide transporter PepT1, shorter 
peptides with two or three amino acids are absorbed undamaged through the brush border membrane (Vermeirssen et 
al., 2004). Peptide IPP and VPP are two well-documented peptides. They are derived from milk which possesses the 
ACE inhibitory activity. Using various models, it was found that these two peptides were readily transported through 
the intestinal epithelium. It has been described that IPP escapes gastrointestinal digestion and can pass in the human 
circulatory system undamaged (Ryan et al., 2011).  
As for longer intact peptides, paracellular and transcellular routes were suggested although debates are still 
going on regarding the relative importance of the routes. Via the paracellular route, large water-soluble peptides pass 
through the tight junctions between cells. On the other hand, highly lipid soluble peptides seem capable of diffusing 
through the transcellular route. Apart from these, peptides also possibly enter the enterocytes through endocytosis. 
Biologically active peptides produced in food can be absorbed intact via the intestine and yield biological effects at the 
tissue level. Yet, the effectiveness of the given peptides drops as the chain-length increases. In the case of infants, the 
gastrointestinal barrier is not yet fully developed, thus, intact peptides and proteins are much well absorbed in infants 
compared to adults (Vermeirssen et al., 2004).  
An interesting study was carried out by Ryan et al. (2011) to study the peptide resistance towards peptidases 
and its transportation at the brush boarder where the ACE inhibitory peptide LHLPLP from β-casein was used. Due to 
partial hydrolysis by brush border peptidases, HLPLP was formed from the parental sequence. With a concentration 
dependent manner, the hydrolysed peptide was promptly absorbed through the Caco-2 cell monolayer. By the in vitro 
approach, the hydrolysed peptide was also shown to be resistant towards serum proteases and remained intact after one-
hour incubation in the human plasma. 
 
Mode of administration in vivo  
 
Other than oral route, peptides can be administered intravenously (IV). Compared to the oral route, injection 
of the peptide through IV will produce 100% bioavailability. Large peptide easily entered the circulation but comparing 
the easiness to administer the drug in patients, the oral route is much preferred. The antihypertensive activity of peptide 
LRPVAA with an IC50 value of 4.14 µM was studied using SHR where the peptide was administered via IV. The most 
significant reduction of the elevated blood pressure was recorded at the rate of 1 nmol/ml/kg. The reduction of the 
blood pressure by this peptide was calculated as 210% of captopril (10 pmol/ml/kg) where this drug was used as a 
positive control (Lee et al., 2006b). 
 
Other blood lowering pathways 
 
Apart from ACE, chymase can convert angiotensin I to angiotensin II. Both ACE and chymase are present in 
the RAS and kallikrein-kinin system and thus, inhibiting ACE alone may not be sufficient to reduce blood pressure. 
Thus, even though some peptides are very potent for ACE inhibition, due to the complex system of regulating blood 
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pressure, their ACE inhibition activity cannot be observed in vivo. According to Iwaniak et al., (2014), they also agreed 
that sometimes the results of in vitro and in vivo produced by peptides do not correlate with each other possibly due to 
the regulation of blood pressure by factors other than ACE.  
 
RAS is not the only pathway that regulates blood pressure. It is possible that these peptides inhibit other 
mechanisms in vivo and cause a significant reduction in blood pressure. Apart from the ACE inhibition, a few other 
antihypertensive mechanisms induced by a peptide derived from food have been reported as endothelin converting 
enzyme (ECE) and endothelin 1 (ET-1) release inhibition, arginine-nitric oxide pathway inhibition, renin inhibition, 
calcium channel blocking and angiotensin receptor blocking (Udenigwe & Mohan, 2014). Thus, this may explain why 
some peptides with high IC50 value for ACE inhibition in vitro have good blood pressure lowering property in vivo. 
Another reason why in vivo analyses have to be carried out is that the pattern of blood pressure lowering could 
be monitored, which may be unsuitable for patients even if the peptide is very potent. For example, after administered 
orally in SHR, dipeptide with tyrosine at the C-terminal will produce a slow but prolonged systolic blood pressure 
reduction. However, when phenylalanine is present in dipeptides at the C-terminal, it resulted in a more rapid reduction 
and the duration of action becomes shorter (Vermeirssen et al., 2004). Since phenylalanine is hydrophobic and aromatic 
while tyrosine is aromatic amino acid, the interaction of these peptides to the ACE’s S1, S1’, and S2’ subunits may 
differ according to the nature of the amino acids. 
 
Conclusion 
 
Knowledge of the structure-activity relationship of the ACE-inhibitory peptides is still limited. Apart from the 
proline residue positions in the peptide sequence, other residues have not been completely studied which lead to the 
difficulties in predicting the potent sequence. Compared to the N-terminal of the peptide, C-terminal of the peptide 
amino acids sequence is utmost importance in order for the peptide to bind to the ACE active site. Although the ACE 
inhibitory activity of a peptide can be predicted from the amino acids residue arrangement, it does not necessarily give 
a positive outcome, especially when in vivo test is carried out. To retain its activity, it is important for the peptide not to 
be hydrolysed by gastrointestinal system and readily absorbed into the blood circulation. Since some of the peptides 
will be hydrolysed by the action of trypsin, pepsin, pancreatin based on the cleavage site in the sequences, their activity 
in vivo is questionable. Peptide administered through IV route produced good ACE inhibition. However, although this 
route can provide 100% bioavailability, this is not a practical way of a nutraceutical administration if care is to be taken 
on the easiness of nutraceutical administration in patients for treatment purposes.  
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